The calcium-sensing receptor and the hallmarks of cancer  by Tennakoon, Samawansha et al.
Biochimica et Biophysica Acta 1863 (2016) 1398–1407
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrReviewThe calcium-sensing receptor and the hallmarks of cancer☆Samawansha Tennakoon a,1, Abhishek Aggarwal a,b,1, Enikö Kállay a,⁎
a Department of Pathophysiology and Allergy Research, Medical University of Vienna, Austria
b Department of Pediatrics/Endocrinology, Stanford University School of Medicine, Stanford, CA, USAAbbreviations: 1,25-D3, 1,25-Dihydroxy vitamin D3
Adenylate cyclase; ADH, Autosomal dominant hypocalcae
ceptor; cAMP, Cyclic adenosine 3′,5′-monophosphate; Cai2
cium; Cao2+, Extracellular free ionised calcium; CRC, Color
domain; EGFR, Epithelial growth factor receptor; EM
transition; ER, Endoplasmic reticulum; FHH, Familial hy
proteins, Guanine nucleotide-binding proteins; GI, Gast
coupled receptor; HCO3−, Bicarbonate ion; HHM, Humoral
mGluRs, Metabotropic glutamate receptors; miRNA, Micr
hyperparathyroidism; OR, Odds ratio; PKC, Protein kinas
Phospholipase A; PLD, Phospholipase D; PTH, Parathyroid
hormone-related peptide; RANKL, Receptor activator of
Renal cell carcinoma; SNP, Singlenucleotide polymorphism
tential canonical 1; TM, Transmembrane domain; VDR, Vit
D response element.
☆ This article is part of a Special Issue entitled: Calcium
Jacques Haiech, Claus Heizmann, Joachim Krebs, Thierry C
⁎ Corresponding author at: Department of Pathophy
Medical University of Vienna, Währinger Gürtel 18-20, A-
E-mail address: enikoe.kallay@meduniwien.ac.at (E. K
1 These authors contributed equally.
http://dx.doi.org/10.1016/j.bbamcr.2015.11.017
0167-4889/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 9 October 2015
Received in revised form 17 November 2015
Accepted 18 November 2015
Available online 30 November 2015The calcium-sensing receptor (CaSR) plays a pivotal role in systemic calciummetabolism by regulating parathy-
roid hormone secretion and urinary calcium excretion. The CaSR is ubiquitously expressed, implying a wide
range of functions regulated by this receptor. Abnormal CaSR function affects the development of both
calciotropic disorders such as hyperparathyroidism, and non-calciotropic disorders such as cardiovascular dis-
ease and cancer, which are the leading causes of mortality worldwide.
The CaSR is able to bind a plethora of ligands; it interacts with multiple G protein subtypes, and regulates highly
divergent downstream signalling pathways, depending on the cellular context. The CaSR is a key regulator for
such diverse processes as hormone secretion, gene expression, inﬂammation, proliferation, differentiation, and
apoptosis. Due to this pleiotropy, the CaSR is able to regulate cell fate and is implicated in the development of
many types of benign or malignant tumours of the breast, prostate, parathyroid, and colon. In cancer, the CaSR
appears to have paradoxical roles, and depending on the tissue involved, it is able to prevent or promote tumour
growth. In tissues like the parathyroid or colon, the CaSR inhibits proliferation and induces terminal differentia-
tion of the cells. Therefore, loss of the receptor, as seen in colorectal or parathyroid tumours, confers malignant
potential, suggestive of a tumour suppressor role. In contrast, in prostate and breast tumours the expression of
the CaSR is increased and it seems that it favours metastasis to the bone, acting as an oncogene.
Deciphering themolecularmechanismdriving the CaSR in the different tissues could lead to development of new
allosteric drug compounds that selectively target the CaSR and have therapeutic potential for cancer. This article
is part of a Special Issue entitled: Calcium and Cell Fate . Guest Editors: Jacques Haiech, Claus Heizmann, Joachim
Krebs, Thierry Capiod and Olivier Mignen.
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The extracellular calcium-sensing receptor (CaSR) is a ubiquitously
expressed class C G-protein coupled receptor (GPCR), the master
regulator of calciumhomeostasis [1,2]. It is highly expressed in the para-
thyroid and thyroid glands and in the kidneys [2]. In foetal tissues, the
CaSR is abundant in the peripheral nervous system, heart and the
lungs [3], suggestive of a role in the development of these organs. The
CaSR was identiﬁed as themolecular sensor of free ionised serum calci-
um (Cao2+) [4]. Ca2+ plays the role of ﬁrst messenger for the CaSR and
links changes in extracellular Ca2+ concentration with intracellular sig-
nalling networks critical for many physiological and pathological pro-
cesses [1]. Besides the systemic regulation of Cao2+ homeostasis, the
CaSR controls numerous other processes, such as axon and dendrite de-
velopment in the brain, regulates insulin secretion, blood pressure and
myogenic tone, bone remodelling, intestinal water absorption and pH
regulation, synthesis of enteroendocrine hormones, and transport of
calcium into milk. On cellular level, it regulates gene expression, cell
proliferation, differentiation, and cell death. The CaSR responds to
numerous signalling molecules, such as other cations, metabolites,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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faceted receptor with multiple ligands and pleiotropic effects [1].
In the present review we explore the multiple signalling pathways
regulated by this multimodal chemosensor in cancer, to understand
how the pleiotropy of the CaSR reﬂects on its contradictory roles in tu-
mour development.
1.1. The structure of the CaSR
The CASR gene is located on the long arm of chromosome 3 (3q13.3-
21) and consists of seven exons. It is under the control of two promoters
(the upstreamP1 containing a TATAbox and a CAATbox, and the down-
streamP2,which is GC rich) that result in alternative transcripts of exon
1 (exon 1A and exon 1B) [5]. Expression of exon 1A is lower in parathy-
roid adenomas compared with the normal parathyroid tissue [6]. In
colorectal tumours, exon 1A mRNA levels inversely correlate with tu-
mour grade [7]. Therefore, it appears that exon 1A has more impact on
CaSR expression than exon 1B. The presence of the two promoter
regions suggests tissue-speciﬁc CASR promoter regulation and alterna-
tively spliced mRNA transcripts [6,8]. Both promoters contain vitamin
D response elements (VDREs) enabling 1,25-dihydroxy vitamin D3
(1,25-D3), the active form of vitamin D, to induce CaSR expression [5].
The CaSR, a large, 1078 amino acid long protein, consists of
four major domains: a large extracellular N terminal domain (ECD), a
cysteine-rich domain linking the ECD to the ﬁrst transmembrane
helix, the seven-transmembrane (TM) domain, and an intracellular C-
terminal domain [9,10]. The large extracellular domain, characteristic
of several GPCRs, is organised as a Venus-ﬂytrap structure. This motif
contains the majority of ligand binding sites of the CaSR, others are
found in the transmembrane domain. Because the crystal structure of
the CaSR is still not known, most of the predictions on the regions in-
volved in ligand binding are performed using the X-ray structure of
the metabotropic glutamate receptors (mGluRs) [11] which belong to
the sameGPCR family. Naturally occurringmutations aremost common
in the ECD [12]. TheN-terminus of this domain contains a signal peptide
cleavage site. The conserved cysteine rich domain is important for re-
ceptor dimerization, cell surface expression, and signalling [13]. The
216 amino acid long intracellular tail is crucial for CaSR signalling and
for surface expression [14].
During its biosynthesis, the signal peptide targets the CaSR to the en-
doplasmic reticulum (ER) where it is dimerized and then glycosylated
in the Golgi before reaching the cell surface [15,16]. Although the CaSR
is usually present as a homodimer at the cell surface, the CaSR can
form heterodimeric complexes with other GPCRs like the glutamate re-
ceptors or the γ-aminobutyric acid-B receptor 1 and can also bind to
other proteins like ﬁlamins, dorﬁn, and β arrestins [17,18]. Dimer for-
mation is important, but not sufﬁcient to release the CaSR from the ER
pool.
In contrast to most GPCRs, binding to its ligands does not lead to
desensitisation of the CaSR [15]. Grant et al. have demonstrated that al-
though endocytosis remains active, CaSR signalling drives biosynthesis
of the receptor, release of the new receptor molecules from the ER
pool, and trafﬁcking and insertion to the plasmamembrane, a phenom-
enon known as the agonist-driven insertional signalling [19].
1.2. The role of the calcium-sensing receptor in physiology
1.2.1. Role of the CaSR in calciotropic tissues
The primary function of the CaSR ismaintenance of systemic calcium
homeostasis, bymaintaining the balance between absorption of Ca2+ in
the gastro intestinal (GI) tract, excretion of Ca2+ by the kidneys, and the
release of Ca2+ from the bone. The CaSR in the parathyroid senses min-
ute changes in serum calcium levels (1.1–1.3 mM) and regulates para-
thyroid hormone (PTH) synthesis and secretion. When serum Ca2+
levels are high, the receptor is activated, inhibiting PTH synthesis and
secretion. When serum Ca2+ concentration is low, CaSR is inactive,and PTH is secreted into the serum. This enhances Ca2+ uptake from
the intestine, Ca2+ release from the bone and reduces urinary Ca2+ se-
cretion until serum Ca2+ concentration is restored [1]. Renal CaSR con-
trols calcium and phosphate homeostasis, ion transport, the release of
renin, and maintains urinary acidiﬁcation and concentration [16]. In
the bone, the CaSR is involved in bone cell metabolism, osteogenesis
and in linking bone formation to resorption during bone remodelling
[20], although the role of the CaSR in skeletal development is still
controversial [21,22]. CaSR mediated reduction in calcitonin secretion
in response to low extracellular calcium is also considered important
in maintenance of systemic calcium homeostasis. Calcitonin inhibits
bone resorption while increasing urinary Ca2+ excretion [23].
1.2.2. Role of the CaSR in non-calciotropic tissues
Although the central role of theCaSR is regulation of calciumhomeo-
stasis, the CaSR is expressed in non-calciotropic tissues as well. In these
tissues, the CaSR regulates a multitude of cellular processes [1]. In the
central nervous system, the CaSR is involved in regulation of neuronal
cell growth as well as maturation and function of oligodendroglial
cells. In nerve endings, the CaSR regulates synaptic functions like plas-
ticity and neurotransmission [24]. In the epidermis, the CaSR regulates
cell–cell adhesion and differentiation [25]. In the breast, the CaSR is in-
volved in lactation and enables Ca2+ transport intomilk [26]. In the pan-
creas, the CaSR mediates cellular adhesion, cell-to-cell communication
and insulin secretion [27]. In the cardiovascular system, the CaSR regu-
lates blood vessel tone and blood pressure [28].
The CaSR is also expressed along the entire GI tract including the
taste buds [29], oesophagus [30], stomach [31], and the small and
large intestine [32]. In the gut the CaSR is considered to serve as a nutri-
ent sensor [33]. The CaSR stimulates theH+-K+-ATPase, thus regulating
secretion of gastrin from G cells of the stomach [34]. It also stimulates
secretion of cholecystokinin from enteroendocrine cells [35,36], and se-
cretion of bone morphogenetic protein 2 [37] and Wnt5a from colonic
myoﬁbroblasts [38]. In the intestine, the CaSR is involved in regulating
ﬂuid transport and intestinal ion transport. Bicarbonate (HCO3−) secretion
in the colon is ﬁne-tuned by the CaSR: in physiological settings it stimu-
lates chloride- and short fatty acid-dependent secretion of HCO3−, while
in experimental conditions resulting in HCO3− loss, that also occurs in di-
arrhoea and cholera, the CaSR inhibits cAMP-dependent HCO3− secretion
[39].
1.3. CaSR-mediated signalling
The CaSR is a promiscuous receptor that recognises many different li-
gands. Upon ligand binding, the conformation of the CaSR changes, lead-
ing to binding and activating of associated guanine nucleotide-binding
proteins (Gproteins) and initiating a complex, Gprotein-mediateddown-
stream signalling. Depending on the cell and tissue type the CaSR acti-
vates a whole network of speciﬁc signalling cascades, tightly regulating
not only calcium homeostasis but also several pivotal cell functions such
as proliferation, differentiation, and apoptosis [40,41]. Moreover the
quantity of the CaSR in the cell affects its own signalling as shown recently
by Brennan et al. [42].
1.3.1. CaSR ligands
CaSR is activated by a plethora of ligands (Table 1). Type-I or
orthosteric ligands directly activate the receptor whereas, type-II
ligands are allosteric modulators which sensitise the receptor to type-I
ligands [11].
Ca2+ is the main orthosteric physiological ligand of the CaSR. Five
putative Ca2+ binding sites were identiﬁed in the ECD [43]. Site 1 is lo-
cated in the hinge region between the two lobes of theVenus-ﬂytrap re-
gion. The sites 1, 2, and 4 are considered non-continuous while the sites
3 and 5 are continuous binding sites. The binding of Ca2+ to the different
binding sites impacts differently the binding of subsequent Ca2+ ions
and produces highly cooperative intracellular Ca2+ responses.
Table 1
CaSR ligands and physiological conditions which affect CaSR activity.
Type I ligands Cations




Polyarginine, polylysine, protamine, γ-glutamyl
peptides, amyloid-β peptide
Aminoglycoside antibiotics
Neomycin, tobramycin, gentamicin, kanamycin
Type II ligands Pharmacological agents
Positive modulators (calcimimetics): Cinacalcet,
NPS R-467, NPS R-568, AMG 641
Negative modulators (calcilytics): NPS 2143, Calhex
231, compound 3, Ronacaleret
Amino acids
L-Trp, L-Phe, L-His, L-Ala, L-Glu, L-Leu, L-Arg
Physiological conditions Ionic strength, pH
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depends on the concentration of the extracellular Ca2+ [44].
A number of other cations can also activate the CaSR (Table 1). Ex-
periments with chimeric receptors suggest that the different cations
bind to different regions in the extracellular domain of the CaSR [11].
In addition to the cations, amino acids, such as large aromatic L-amino
acids, bind to the ECD and act as allosteric modulators. Their binding
site is different from the Ca2+ binding pockets [45]. Endogenous poly-
amines, even aminoglycoside antibiotics activate the receptor, broaden-
ing the range of CaSR ligands [1,11,44]. Ligand binding to the CaSR
modulates subsequent ligand-receptor interaction, leading either to
homotropic cooperativity if the ligands are identical, or to heterotropic
cooperativity, if they are different (i.e. Ca2+ and an aromatic amino
acid) [44].
Physiological conditions such as ionic strength and pH also affect
CaSR activity. Ionic strength reduces, whereas pH levels higher than
the physiological levels (7–7.8) increase the sensitivity of the receptor
towards the agonists [46,47].
In addition to these biological ligands, pharmacological modulators:
calcimimetics and calcilytics were developed to target the CaSR
(Table 1). These not only modulate the activity of the receptor, but act
also as pharmaco-chaperones and inﬂuence CaSR expression as well.Fig. 1.Gprotein activation anddownstreamsignalling of the active CaSR. The spectrumof CaSR l
physiological conditions. Intracellular Ca2+ signal, cAMP synthesis, and protein phosphorylatioCalcimimetics increase the number of CaSR molecules on the cell sur-
face, whereas calcilytics either downregulate [48] or upregulate CaSR
expression [49] in a cell type-dependent manner. Experiments
performed by Huang and Breitwieser using proteasomal inhibitors sug-
gested that NPS 2143-dependent downregulation of the CaSR expres-
sion was due to increased sensitivity to degradation [48].
Ca2+ and calcimimetics trigger the phosphorylation of Thr888 in the
C terminal domain of the CaSR. The CaSR antagonist NPS 2143
prevented this phosphorylation and decreased CaSR activity [50]. Da-
vies et al. demonstrated that de-phosphorylation of Thr888 inhibited
CaSR signalling [50], identifying this process as a negative feedback
loop in the regulation of CaSR function.
1.3.2. G protein activation and downstream signalling
The calcium-sensing receptor regulates diverse downstream signal-
ling pathways by binding different G protein subunits. Kinetics of G pro-
tein activation depend on a number of factors including receptor type,
ligands, intracellular protein content, expression of G proteins and
their binding afﬁnity and deactivation rate of the receptor [51]. To
date, four classes of Gα subunits (Gi/o, Gs, Gq/11 and G12/13) have been
shown to be involved in CaSR-mediated signalling, activating complex
downstream pathways (Fig. 1) [52].
Coupling of the CaSR to Gαq/11 leads to phospholipase C (PLC)
activation, IP3-mediated intracellular Ca2+ (Cai2+) release and protein
kinase C (PKC) activation (Fig. 1) [1,52,53]. CaSR-dependent upregula-
tion of PLC/IP3-mediated Cai2+ levels have been observed in liver cells
[54], parathyroid cells [4,55], lung epithelial cells [56], and kidney cells
[57]. CaSR-mediated activation of phospholipase (PL) C, A, and D is
dependent on PKC stimulation [1,58,59]. The CaSR itself can be phos-
phorylated by PKC on its PKC-phosphorylation sites (Thr888, Ser895,
Ser 915) [14].
In parathyroid cells, coupling of the CaSR to Gi/o, leads to inhibition of
adenylate cyclase (AC) reducing the level of 3′,5′-cyclic adenosine
monophosphate (cAMP) and inhibition of CaSR-mediated PTH secre-
tion [1,58]. Upregulation of AC activity triggers PKA activation via
cAMP generation. PKA signalling, Ca2+/CAM/calcineurin and MAP/ERK
pathway are the main downstream events regulated by cAMP [60,61].
This in turn regulates a wide range of downstream proteins amplifying
and diversifying the initial signal. CaSR-mediated Gi/o activation has
been reported in the cells of the medullary thick ascending limb [62],
in human embryonic kidney cells transfected with CaSR [63], and inigands includes endogenous cations, polyamines, aminoacids, pharmacological agents, and
n are some of the key signalling events regulated by the CaSR.
Fig. 2. The yin-yang role of the CaSR in cancer: In cancer the CaSR regulates proliferation,
differentiation, cell death, angiogenesis, andmigration. It functions either as a tumour sup-
pressor as in colon, parathyroid, gastric cancer, and neuroblastomas (shown in green) or
as an oncogene in breast, prostate, ovary, and kidney cancer (shown in red).
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ulated [64]. Mamillapalli et al. demonstrated that CaSR is coupled to Gi/o
in normal breast cells whereas it binds to Gs, in breast cancer cells [64].
In addition to breast cancer cells, CaSR-mediated synthesis of cAMP via
activation of Gs has been observed in pituitary cells [65], hamster ovary
cells [66], and in colon cancer cells [7].
G12/13-mediated CaSR signalling primarily inﬂuences cell shape and
cell migration by activation of Rho GTPases [67] andmodulation of pro-
cesses involved in maintaining cell architecture such as β-catenin re-
lease from E-cadherin [52,68]. Understanding the crosstalk within and
between cellular signalling networks is crucial not only for identifying
molecular basis of pathological conditions but also for the development
of novel therapeutic agents.
1.3.3. Biased signalling of the CaSR
The CaSR functions as a multimodal chemosensor and a key trans-
ducer of signals from the extracellular milieu to the intracellular envi-
ronment. It integrates a variety of extracellular metabolic stimuli (e.g.
polyvalent cations, amino acids, pH, and ionic strength), which prefer-
entially activate distinct intracellular signalling cascades in a process
known as “ligand-directed targeting of receptor stimulus” or “stimulus
bias” [52,69].
CaSR signalling depends on the type of the cell, expression of G pro-
tein isoforms, enzymes, and adapter proteins that control the assembly
of signalling scaffolds, and mutations of the receptor [52,68,69]. The
phenomenon of ligand-dependent bias is used as a new strategy to de-
velop GPCR-targeting drugs, including CaSR-targeting candidates, with
very speciﬁc on-target effects and no, or minimal side-effects [69,70].
Due to the diversity and versatility of the CaSR-mediated signalling,
the CaSR has very different roles in different tissues and pathologies.
1.4. CaSR mutations and their clinical implications
Aberrant CaSR expression and activity is linked to several
inherited disorders of calcium homeostasis. Numerous CASR muta-
tions, both activating and inactivating, have been identiﬁed in
humans (http://www.casrdb.mcgill.ca/). The best-characterised dis-
orders caused by inactivatingmutations are disorders of calciumme-
tabolism including familial hypocalciuric hypercalcaemia (FHH) and
neonatal severe hyperparathyroidism (NSHPT). FHH is an autosomal
dominant disorder associated with increased serum Ca2+, inappro-
priately normal PTH levels and decreased urinary Ca2+ excretion as
a result of loss of function mutations of the CaSR on a single allele [58,
71,72]. NSHPT, caused by homozygous inactivating mutations is
characterised by life threatening hypercalcaemia and under-mineralized
bones [58,72]. Gain of functionmutations of the CASR result in autosomal
dominant hypocalcaemia (ADH) and type-V Bartter syndrome. ADH
patients have mild hypocalcaemia, low PTH levels, seizures during
childhood, while the type-V Bartter syndrome is characterised by chronic
metabolic alkalosis, hypocalcaemia and increased plasma renin activity
[58,73].
2. The calcium-sensing receptor in cancer
Outside its central role in calcium homeostasis, the CaSR mediates
cell fate-regulating processes including hormone secretion, control of
proliferation, differentiation, apoptosis, and chemotaxis [1]. The ability
of the CaSR to regulate cell fate predicts that it will have substantial im-
pact in cancer development. Interestingly, the CaSR functions in a yin-
yang fashion acting both as an oncogene and a tumour suppressor
gene, depending on the site of cancer (Fig. 2).
Several groups have tested whether common genetic variants of the
CASR inﬂuence the risk, incidence, recurrence, or lethality of cancers. In
a large cohort, nested in the prospective Health Professionals Follow-up
study, three genetic variants of the CASRwere linked with lethal prostate
cancer. Two single nucleotide polymorphisms (SNPs) were nominallyassociated with odds ratios (OR) of 0.65 (rs6438705; rs13083990), the
third (rs2270916) was linked to an OR of 1.55, while 3 others
(rs1801725, rs1042636, and rs1801726) showed no associations [74]. A
recent study however, found no association between 65 CASR SNPs and
the recurrence or aggressiveness of prostate cancer [75].
The G allele of the CaSR rs17251221 polymorphism seems to protect
against ovarian cancer [76].
Three nonsynonymous SNPs in the coding region of the intracellular
CASR tail (Q1011E, A986S, R990G) have been suggested to be linked to co-
lorectal cancer susceptibility [77]. TheCASR SNP rs1801726 (Q1011E)was
signiﬁcantly associated with reduced risk for rectal cancer [78]. Another
study identiﬁed four polymorphisms signiﬁcantly associated with in-
creased colorectal cancer risk, but only in patients that received low calci-
um diet [79].
In a cohort of neuroblastic tumours three functionally relevant CaSR
polymorphisms (rs1801725, rs1042636 and rs1801726) were analysed
as a block, the tri-locus haplotype TAC, that suggests a potentially less
active CaSR, was associated with an increased risk of death in the
whole cohort including the neuroblastoma patients [80]. Apart from
the SNPs, there is no real evidence until now, that would link CASRmu-
tations to cancer development. It appears that it is the expression level
of the receptor that changes during cancer development. It is either in-
creased, as in cancers where the CaSR acts as an oncogene, or decreased,
as in cancers where it functions as tumour suppressor [68].
2.1. The CaSR: an oncogene
In several cancers, such as prostate, testicular, ovarian, and breast
cancer the CaSR seems to act as an oncogene, often by promoting prolif-
eration and inhibiting apoptosis. However, the mechanisms are not yet
completely understood.
2.1.1. Humoral hypercalcaemia of malignancy
The oncogenic role of the CaSR is often linked to its involvement
in regulating the synthesis of parathyroid hormone-related peptide
(PTHrP) [81]. PTHrP is a peptide growth factor that binds the same re-
ceptor as PTH. It is a stimulator of osteoclastic bone resorption that acti-
vates osteoclasts by increasing the expression of receptor activator of
nuclear factor κ B ligand (RANKL), amember of the tumour necrosis fac-
tor cytokine family [81]. PTHrP contributes to the pathogenesis of can-
cers by stimulating osteolytic bone destruction and releasing bone-
1402 S. Tennakoon et al. / Biochimica et Biophysica Acta 1863 (2016) 1398–1407derived growth factors. Humoral hypercalcemia of malignancy (HHM)
is a common paraneoplastic syndrome and a frequent complication of
breast, prostate, lung, kidney cancer and of multiple myeloma. HHM is
often caused by PTHrP produced by tumour cells [82,83] and is
frequently seen in patients with tumours that metastasize to the bone.
One of the ﬁrst evidences that the CaSR might be involved in the
pathophysiology of HHM was based on studies in the Rice H-500 rat
Leydig tumour cell line [84]. These cells cause PTHrP-dependent
hypercalcaemia in rats bearing Leydig tumour fragment xenografts.
Treatment of H-500 cells with Ca2+ resulted in a concentration-
dependent increase of PTHrP release [84], an effect that could be
inhibited by the transfection of these cells with a dominant negative
CASRmutant (bearing the R185Q mutation) [85].
In H-500 cells, the CaSR stimulated proliferation and conferred resis-
tance to apoptosis [86], although this effect seemed to be direct, by acti-
vation of the PI3-kinase/Akt pathway, and not mediated by PTHrP [87].
In the H-500 cells, activation of the CaSR increased the expression of
the pituitary tumour-transforming gene [88], an oncogene that affects
proliferation and angiogenesis, two hallmarks of cancer (Fig. 3).
2.1.2. The role of the CaSR in favouring metastasis to the bone
The bone niche has unique characteristics that provide homing sig-
nals to several cancers such as breast, prostate, lung and kidney cancer.
These cancers develop bone metastases with an incidence of 65–40%
[89]. Multiple growth factors and cytokines in combination with physi-
cal properties provide favourable chemotactic and growth-promoting
conditions [90]. High extracellular Ca2+ is one of themost important in-
organic factors involved in this process [91]. A recent study showed that
in the highly invasive MDA-MB-231 breast cancer cell line activation of
the CaSR stimulated the secretion of several pro-angiogenic and chemo-
tactic cytokines and growth factors [92]. The CaSR seems to facilitate
formation and growthof skeletalmetastases of prostate, breast, and kid-
ney cancer cells [81].
Prostate cancer metastasizes almost exclusively to bone. The CaSR is
higher expressed in the bone metastases than in the primary prostate
tumour, although no differenceswere seen in primary prostate tumours
with orwithout concurrentmetastases [93]. High Cao2+ increased prolif-
eration of bone-colonising prostate cancer cell lines (PC-3, C4-2B) but
had no effect on the LNCaP prostate cancer cells derived from a lymph
node metastasis. The proliferative effect of Cao2+ was mediated by the
CaSR, at least in part, because knocking down CaSR expression inhibited
proliferation and metastatic potential of PC-3 cells [91].
About 30–40% of renal cell carcinomas (RCC) metastasize to the
bone. A recent study found that expression of CaSR was highest in the
primary renal cell tumours of patients with bonemetastases, compared
with tumours from patients with lung metastases or no metastases.
Moreover, Cao2+ treatment induced proliferation and migration solely
in RCC cells obtained from patients with bone metastases, an effect
that was inhibited by the CaSR inhibitor NPS 2143 [94].
Understanding the role of the CaSR in development of bone metasta-
ses could provide new application for CaSR targeting drugs. Antagonising
the tumour cell CaSR with calcilytics that prevent its activation in
conjunction with antiresorptive agents, such as bisphosphonates, might
result in a novel therapeutic approach to control both osteolysis and tu-
mour cell proliferation.
2.1.3. Mitogenic pathways stimulated by the CaSR
Among early responses to mitogenic GPCR agonists is the activation
of protein phosphorylation cascades, including Akt/mTOR/p70S6K, Raf/
MEK/ERK, and PKC/PKD [95]. The tumour promoting effects of the CaSR
seem to involve the same or similar pathways. Thus, stimulation of the
CaSR by Cao2+ induced proliferation in both normal andmalignant ovar-
ian epithelial cells by activation of the ERK1/2 pathway [96,97].
The signalling pathways underlying the mitogenic effects of the
CaSR in prostate cancer are still not completely understood. Although
most of the prostate cancer cells cause osteoblastic and not osteolyticmetastases, PTHrP seems to be involved in the CaSR-mediated stimula-
tion of metastasis. PTHrP levels were higher in prostate tumours com-
pared with normal prostate epithelial cells. Moreover, PTHrP increased
proliferation of the bone metastasizing PC-3 cells but not that of LNCaP
cells [98]. Activation of the CaSR in prostate cancer cells stimulated
PTHrP secretion probably by transactivation of the epithelial growth fac-
tor receptor (EGFR) and activation of ERK1/2 [99]. Knockdown of PTHrP
in PC-3 cells inhibited epithelial-to-mesenchymal transition (EMT) and
tumour progression when injected orthotopically in mice [100]. There is
some evidence suggesting a novel linkage between PTHrP and the Wnt
pathway. PTHrP inhibits the expressionofDickkopf-1, a canonicalWnt in-
hibitor, leading to activation of the Wnt pathway in the bone metastases
of prostate cancer [101].Whether the CaSR is involved in thismechanism,
needs to be proven. A further pathway involved in the CaSR-mediated
proliferation is activation of Akt [91], while another seems to involve
Rho signalling [102].
2.1.4. The role of the CaSR in breast cancer
The CaSR is expressed both in the normal and cancerous mammary
gland. In normal mammary epithelial cells activation of the CaSR during
lactation inhibits PTHrP synthesis and secretion. In contrast, in breast
cancer cells the CaSR stimulates PTHrP secretion in a cAMP-dependent
way [103]. This contradictory function is possible due to the ability of
the CaSR to bind and activate different G proteins, in this case, to switch
from activation of the inhibitory Gαi and suppression of cAMP levels in
the normal mammary cells, to activation of Gαs and stimulation of
cAMP levels in breast cancer cells [64].
It seems that the role of the CaSR in breast cancer is equivocal [103].
There is evidence both for pro- and anti-tumourigenic effects. Mihai
et al. [104] found positive correlation between CaSR expression in pri-
mary breast tumours and the development of osteolytic bone metasta-
ses and showed that the CaSR expressionwas higher in bonemetastases
than in primary breast tumours.
Recently Li et al. observed that lower expression of CaSR signiﬁcantly
associated with poor overall survival, cause-speciﬁc survival, and dis-
tant metastasis-free survival of breast cancer patients [105]. Additional-
ly, in a large prospective cohort, postmenopausal womenwith a dietary
calcium intake of N1250mg/d had reduced risk to develop breast cancer
[106].
Several studies suggested that the CaSR promoted a more aggressive
behaviour of breast tumours. Treatment with high calcium concentration
(N 15mM) reduced oestrogen receptor expression but increased its tran-
scriptional activity in the breast cancer cell line MCF-7 transfected with a
vector containing oestrogen response element and a luciferase reporter
gene. Activation of the CaSR by the calcimimetic NPS R-467 mimicked
the effect of Ca2+ on oestrogen receptor expression and activity [107].
InMCF-7 cells activation of the CaSRwith increasing Cao2+ levels stimulat-
ed proliferation and transient receptor potential canonical 1 (TRPC1)
channel expression in a PLC-, PKC-, and ERK-dependent manner [108,
109]. The effect of the CaSR involved transactivation of the EGFR [109].
Such “triple-pass” signalling through the CaSR is common for several
cell types [103]. TheCaSRpromotedbreast cancer cellmigration, however
only in cells that are capable to form bonemetastases (e.g. MDA-MB-231
andMCF-7). In BT474 cells, that have no bone-metastatic potential, Cao2+
hadno effect onmigration, although the CaSR levelswere similar as in the
metastatic cells [110].
The group of Chakrabarty [111] however, observed that treatment
with Cao2+ reduced malignant behaviour and induced the sensitivity of
MCF-7 and MDA-MB-435 cells to the chemotherapeutic drug paclitaxel,
by inhibiting the expression of survivin. Moreover, the surviving
paclitaxel-resistant cells expressed no CaSR [111]. This group also sug-
gested that some of the tumour suppressive functions of BRCA1 are
CaSR-dependent [112].
The oncogenic potential of the CaSR is demonstrated by stimulation
of proliferative and angiogenic signals and promotion of metastasis
(Fig. 3). The contradictory ﬁndings with respect to the role of the CaSR
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and show the need to study the effect of the receptor in a more natural
environment, either in organoids or in vivo in animal models.
2.2. The CaSR, a tumour suppressor
Increased intake of calcium reduces the risk of several cancers. There
is some evidence that the CaSR is one of the central mediators of the
anti-tumourigenic effects of calcium. However, expression of the CaSR
is reduced or even lost in several malignancies, including parathyroid
cancer, colorectal cancer and neuroblastomas. In these tumours, loss
of receptor function leads to loss of the protective effects of calcium be-
cause the decrease in CaSR levels affects both key characteristics of the
Cai2+ response at the single-cell level and the proportion of cells
responding to Cao2+ [42]. The mechanisms leading to loss of expression
are different in the different tumours. In neuroblastomas both genetic
and epigenetic mechanisms contribute to silencing of the CaSR; in colo-
rectal tumours the epigenetic mechanisms are primarily responsible for
CaSR loss. However, in parathyroid tumours, neither of these mecha-
nisms seem to be responsible for loss of CaSR expression.
2.2.1. The role of the CaSR in parathyroid cancer
In the parathyroid, expression of the CaSR progressively decreases in
hyperplastic glands, adenomas, and carcinomas compared with normal
parathyroid tissue [113]. An inactivating mutation of the CASR in a
mouse model led to parathyroid hyperplasia [114] suggesting a causa-
tive relation between loss of CaSR function and loss of growth control.
In another study using mice with chronic kidney disease, the authors
demonstrated that treatment with Cinacalcet, a positive allosteric mod-
ulator of the CaSR, was able to control parathyroid hyperplasia, which
was reversed upon discontinuation of the treatment [115].
Although it is clear that loss of CaSR function leads to an increase in
PTH secretion, the molecular mechanisms governing parathyroid
tumourigenesis is not yet clear. Neither loss of CASR alleles [116], nor
epigenetic silencing [117,118] are responsible for the loss of CaSR ex-
pression in parathyroid tumours. Furthermore, no mutations in the
CASR gene were associated with parathyroid hyperplasia [119]. There-
fore, further mechanistic studies are needed to understand the causes
of CaSR loss and to establish the role of the CaSR in parathyroid tumours.
Recently, Fabbri and colleagues have generated a continuous rat para-
thyroid cell line [120], which would aid in understanding the role of
the CaSR in the parathyroid.
2.2.2. The role of the CaSR in neuroblastomas
In neuroblastoma, a malignancy of the sympathetic nervous system,
expression of the CaSR is lost in unfavourable tumours compared with
differentiated tumours, which still express the receptor [121]. Loss of
one chromosome 3 (monosomy), which harbours the CASR gene, as
well as DNA hypermethylation of the CASR promoter region contribute
to silencing of the receptor in this rare form of cancer. It seems that the
CaSR is needed for ERK1/2-mediated induction of apoptosis in neuro-
blastoma cells [122]. A follow up study associated polymorphisms of
the CASRwith poor clinical outcome [80,122].
2.2.3. The role of the CaSR in colorectal cancer
The inverse correlation between calcium intake and risk of CRC has
been known for decades [123], although the mechanisms driving the
protective effect of calcium were not clear. In normal colonic epithelia
calcium inhibits proliferation and induces differentiation. After identiﬁ-
cation of the CaSR on intestinal cells [32,124] it was suggested that the
anti-proliferative effects of calcium were mediated, at least in part, by
the CaSR [32,125,126]. The CaSR is expressed in normal colonic mucosa
and in early adenomas; its expression is already decreased in advanced
adenomas, and lost in late stage undifferentiated tumours [126,127,
128]. Thismight be the reasonwhyduring colorectal carcinogenesis cal-
cium is ineffective or even tumour promoting [129].Compelling evidence from two independent studies demonstrated
that promoter hypermethylation and histone deacetylation lead to
silencing of the receptor in colorectal tumours [127,130]. We have re-
cently demonstrated that a further cause of silencing the CaSR in colo-
rectal tumours was increased expression of the microRNAs (miRNA)
miR-135b and miR-146b [131]. MiRNAs are small non-coding RNAs
which, in addition to DNA hypermethylation and histone deacetylation,
play an important role in epigenetic regulation of gene expression
[132,133]. Singh et al. showed that miR-21, miR-145 and miR135a
also regulate CaSR expression in colon cancer cells [134,135]. It is likely
that deregulation of miRNA expression occurs also in parathyroid tu-
mours, and could be one of the mechanisms behind loss of expression
in those tumours.
Colon cancer cells that lack the CaSR are less differentiated, grow
faster, and in general have a more malignant phenotype [49,134,135].
Dearth of the CASR (both, global and intestine-speciﬁc) increased prolif-
eration [49,136] and led to formation of pre-neoplastic lesions called ab-
errant crypt foci (ACFs) in the colon of mice [137]. Furthermore, the
intestine of the CaSR-KO mice expresses increased levels of inﬂamma-
tionmarkers and ismore susceptible to chemically-induced colitis com-
pared with the intestine of wild type mice [137,138]. Activating the
CaSR (by treatment with the calcimimetic NPS R-568) or increasing its
expression resensitised colon cancer cells to the chemoprotective func-
tions of calcium, inhibiting cell growth, and inducing differentiation and
apoptosis [49]. These studies unanimously demonstrated that the CaSR
plays a central role in mediating anti-tumourigenic effects of calcium in
the colon.
Colorectal cancer is a disease of defective Wnt/β-catenin signalling.
In vitro, in vivo and ex situ studies have linked the loss of CaSR expression
or function to enhancedWnt/β-catenin signalling in the colon. In colon-
ic cells that lack the CaSR nuclear β-catenin expression increased [136,
139] and the Wnt signalling was shifted from the non-canonical to the
canonical Wnt/β-catenin pathway [38,137,140]. Moreover, the cells
had a more mesenchymal and cancer stem cell-like phenotype, [134,
135,139]. Increasing CaSR expression or activity prevented epithelial-
to-mesenchymal transition (EMT) and reduced expression of cancer
stem cell markers [49,139,141]. These studies demonstrate that the tu-
mour suppressive characteristics of the CaSR in the colon are due to the
ability of the CaSR to inhibit several hallmarks of cancer (Fig. 3). It in-
hibits sustained proliferation by regulating the canonical and non-
canonicalWnt pathway, restricts invasion andmetastasis by preventing
EMT and acquisition of stem cell-like phenotype.2.2.4. The role of the CaSR in other cancers
In gastric tissue the CaSR is expressed in gastric epithelial glands and
ganglions, and is downregulated in gastric tumours [142]. A recent
study found a negative correlation between CaSR expression and gastric
cancer invasion suggesting that theCaSRmight act as a tumour suppres-
sor [142].
In the pancreas, the CaSR is highly expressed in the endocrine is-
lets. The pancreatic ducts, exocrine acinar cells, intrapancreatic
nerves and the blood vessels also express the CaSR, albeit at lower
levels [143,144]. While protein expression of the receptor was
found in both normal and neoplastic pancreatic tissue [143,144],
mRNA expression was downregulated in pancreatic ductal adeno-
carcinomas compared with the normal, adjacent tissue from the
same patient [143]. Given the heterogeneous nature of the pancreat-
ic tissue and the differences in the CaSR expression in different
regions, it is still unclear whether the expression of the receptor is
indeed deregulated in pancreatic cancer.
Deregulation of CaSR expression and function contributes to pro-
gression and aggressiveness of several tumours due to its ability to reg-
ulate several hallmarks of cancer (Fig. 3). Finding means or drugs that
modulate CaSR expression and activity in tumours could present the
CaSR as a provocative target for anticancer drug design.
Fig. 3. The CaSR within the hallmarks of cancer as deﬁned by Hanahan andWeinberg. Ar-
rows depict the oncogenic role (in red), and tumour suppressor role (in green). (Adapted
from Hanahan and Weinberg [145]).
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Due to increased life expectancy, cancer in the elderly has become an
increasing problem in theWestern world. Several studies have focused
on establishing risk factors to facilitate the development of effective and
well-tolerated treatments. Targeting the CaSR holds signiﬁcant thera-
peutic potential depending on whether its expression is lost, as seen
in colon and parathyroid cancers, increased as in breast and prostate
cancers, or whether its signalling is altered. CaSR-targeting drugs
could be used to prevent carcinogenesis or to improve the efﬁciency
of current chemotherapeutics.
Although both positive and negative modulators of the CaSR are al-
ready in development, currently only the positive allosteric modulator,
Cinacalcet, is approved for use in humans. It is the ﬁrst FDA-approved al-
losteric GPCRmodulator and is used to treat secondary hyperparathyroid-
ism caused by chronic kidney disease, and hypercalcaemia in patients
with inoperable parathyroid carcinoma [146]. However, it had no effect
on cancer progression, and reduced only the hypercalcaemic symptoms
[147]. Moreover, treatment with Cinacalcet has limits due to its side ef-
fects and tolerability.
Given the implication of the CaSR in many physiological and patho-
physiological processes, allosteric CaSR modulators could be used in
other disorders where the CaSR is involved [148]. Based on preclinical
and clinical studies, several other CaSR-based therapeutics seem to
emerge for non-parathyroid disorders.
Since the CaSR modulates key events in cancer, it presents itself as a
potential therapeutic target. However, caution will be needed when
using CaSR modulators, because of the different roles of the CaSR in
the different malignancies. In order to prevent side effects in other tis-
sues than the target, tissue-speciﬁc delivery should be considered.
Identiﬁcation of ligands or development of drugs with high selectiv-
ity for the CaSR and speciﬁcity for the tissue of interest are needed.
These ligands could be used to exploit the characteristic of the CaSR to
signal in a ligand-biasedmanner; to activate preferentially one pathway
upon binding a speciﬁc ligand, without activating others.
Another strategy could be to ﬁnd natural substances that affect CaSR
expression.We have shownpreviously that high vitaminDdiet increased
CaSR expression in the colon [141]. Whether dietary vitamin Dwould af-
fect the expression level of the CaSR also in tumours, needs to be tested.3. Conclusion
There is evidence for the involvement of the CaSR in the develop-
ment of different tumours. The sheer diversity of the signalling mecha-
nisms affected by the CaSRmakes the identiﬁcation of its precise role in
the different malignancies a challenging task. However, only a deep un-
derstanding of the CaSR-mediated signalling mechanisms in the differ-
ent normal and malignant tissues will provide sufﬁcient support for
the development and use of novel calcimimetics and calcilytics for treat-
ment of cancer.
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